Vitamins & Supplements · Amino acid
BCAAs (leucine, isoleucine, valine)
Leucine, isoleucine and valine · also called BCAAs, branched-chain amino acids, aminoácidos de cadena ramificada
BCAAs are three essential amino acids, leucine, isoleucine and valine, that the body gets from protein foods. They are sold as powders for exercise recovery. Trials found less muscle soreness after hard exercise, mainly in trained people, and small gains in older adults, but little benefit for athletes' performance; the evidence is low-certainty. People with the inherited condition maple syrup urine disease should ask their metabolic doctor before using them.
General information, not medical advice. Last substantive update · Not medically reviewed. A named clinician has not signed off on this page. How this page is made
About BCAAs (leucine, isoleucine, valine)
BCAAs are leucine, isoleucine and valine, three essential amino acids found in protein foods. Trials of supplements show small or uncertain benefits, and a rare inherited condition makes them unsafe.
What BCAAs are
BCAA stands for branched-chain amino acids: leucine, isoleucine and valine. MedlinePlus says amino acids are the building blocks of proteins and that the body can also use them for energy. These three are among the 9 essential amino acids that the body cannot make and must get from food.
Supplements come as powders and capsules that supply these three. Leucine is also sold alone, and many supplements are mixtures with other amino acids or protein.
Where BCAAs come from in food
All protein foods contain them. By USDA data, the three together add up to about: 7.7 g in a cup of roasted chicken breast, 3.9 g in half a cup of firm tofu, 3.4 g in 3 oz of cooked salmon, 3.0 g in a cup of cooked lentils, 2.7 g in a 3 oz broiled beef patty, 1.7 g in a cup of 2% milk, 1.3 g in a large hard-boiled egg and 1.0 g in an ounce of dry-roasted peanuts.
These are the sums of leucine, isoleucine and valine. Food also brings other amino acids and nutrients, and no trial compared food BCAAs with pills.
What the research shows
The best-studied use is exercise. Across 10 trials, BCAAs often lessened soreness after hard exercise, mainly in trained people. In older adults, 35 trials found small gains in strength and muscle mass, but with large differences between trials. For athletes, benefits for performance and body build were negligible.
In cirrhosis, BCAAs probably reduce hepatic encephalopathy (low certainty) with no clear effect on survival. All of this evidence is low or very low certainty, and many trials did not report total protein intake.
Blood levels and type 2 diabetes
Nine observational studies found higher blood levels of all three BCAAs in people who later developed type 2 diabetes. Blood levels reflect many things, including body weight and insulin resistance. The studies do not show that eating or supplementing BCAAs causes diabetes.
Food protein, BCAA pills and mixtures
Food protein gives all the essential amino acids together. BCAA powders give only three. In older adults, many trials used BCAA-rich mixtures, and essential amino acid supplements improved handgrip more than whey protein. So the small gains cannot be credited to BCAAs alone.
At a glance
Traditional uses history, not proof
- An essential part of food protein
- Sold as powders and capsules for exercise recovery
Studied for research
- Essential nutrient role, high certainty
- Muscle soreness after hard exercise, low certainty
- Muscle strength and size in older adults, low certainty
- Athletes' performance and body build, low certainty
- Hepatic encephalopathy in cirrhosis (medical care), low certainty
- Survival in cirrhosis, very low certainty
- Blood levels and type 2 diabetes (observational), very low certainty
Main compounds
- L-leucine
- L-isoleucine
- L-valine
Common forms
- Food sources (meat, fish, eggs, dairy, soy, legumes)
- Powders and capsules
- Oral and intravenous forms used in liver disease trials
Research links: 2021 review: BCAA and muscle soreness (10 trials) · 2022 review: BCAA-rich supplements in older adults (35 trials) · 2022 review: BCAAs in athletes (24 studies) · 2026 Cochrane review: BCAAs in cirrhosis and hepatic encephalopathy · MedlinePlus Genetics: maple syrup urine disease · Research Library · Genes & Biomarkers Library
What it is and its history
- Accepted scientific name
- Branched-chain amino acids (leucine, isoleucine and valine), three essential amino acids
- Common names
- BCAAs (English); Branched-chain amino acids (English); Leucine, isoleucine and valine (English); Aminoácidos de cadena ramificada (Spanish)
- Family or group
- Essential amino acids. MedlinePlus lists leucine, isoleucine and valine among the 9 essential amino acids that the body cannot make.
- Look-alikes and adulterants
- Name: Leucine alone; Note: Sold separately; leucine is the most studied of the three for muscle-building signals (see the athlete and older-adult reviews).; Name: Essential amino acid and protein products; Note: Mixtures and protein powders also contain leucine, isoleucine and valine, and some trials of BCAA-rich supplements used mixtures.
- Sustainability and conservation
- Not assessed.
What is inside, and how it may work
What it contains and how those compounds act in cells and animals. Laboratory and animal mechanisms are not proven effects in people.
Main compounds
| Compound | Family | Where it is concentrated | Activity studied | Level of evidence |
|---|---|---|---|---|
| L-leucine | branched-chain amino acid | See the food values in the Food sources item. | Most studied of the three for muscle-building signals; short-term studies suggest blood ammonia rises at very high intakes. 4 6 | Human data |
| L-isoleucine | branched-chain amino acid | See the food values in the Food sources item. | Essential amino acid; built up in maple syrup urine disease. 7 8 | Human data |
| L-valine | branched-chain amino acid | See the food values in the Food sources item. | Essential amino acid; built up in maple syrup urine disease. 7 8 | Human data |
Mechanisms, receptors and pathways
| Target or pathway | Gene or receptor | What was found | Level |
|---|---|---|---|
| Muscle-building signals | Not named in the abstract | A 2022 review says BCAAs are oxidised in muscle and tended to activate anabolic (muscle-building) signals in athletes, but this did not clearly improve performance or body composition. 6 | Human data |
| Breakdown of BCAAs | BCKDHA, BCKDHB and DBT genes (a protein complex that breaks down leucine, isoleucine and valine) | MedlinePlus Genetics says changes in these genes prevent normal breakdown, so the three amino acids build up in maple syrup urine disease. 8 | Human data |
| Transport competition | Amino acid transporters in the gut and at the blood-brain barrier (not named) | A 2024 review says levodopa competes with branched-chain and other amino acids for limited transport capacity. 9 | Human data |
| Blood levels and diabetes risk | Not applicable | Higher blood BCAA levels are linked to later type 2 diabetes in observational studies; the cause is not shown. 10 | Human data |
Absorption, metabolism and elimination
- Absorption
- Not described in the sources read.
- Distribution
- Not described in the sources read.
- Metabolism
- Oxidised in muscle (athlete review). Broken down by a protein complex whose genes are BCKDHA, BCKDHB and DBT (MedlinePlus Genetics).
- Elimination
- Not described in the sources read.
- Bioavailability
- Not compared between food and supplement forms in the sources read.
Isolated compounds versus whole extracts
Food protein supplies leucine, isoleucine and valine together with other amino acids and nutrients. BCAA powders supply only these three. In trials of older adults, BCAA-rich supplements were often mixtures, and essential amino acid supplements improved handgrip more than whey. No trial compared BCAA pills with food directly.
Nutritional composition
Amino acid contents of foods are from USDA FoodData Central SR Legacy (April 2018 release), read 2026-10-26 from a saved local copy: Chicken breast, roasted, 1 cup chopped (140 g): leucine 3.26 g, isoleucine 2.29 g, valine 2.15 g (total about 7.7 g); Ground beef patty (85% lean), broiled, 3 oz (85 g): leucine 1.23 g, isoleucine 0.7 g, valine 0.78 g (total about 2.7 g); Farmed Atlantic salmon, cooked, 3 oz (85 g): leucine 1.53 g, isoleucine 0.87 g, valine 0.97 g (total about 3.4 g); Hard-boiled egg, 1 large (50 g): leucine 0.54 g, isoleucine 0.34 g, valine 0.38 g (total about 1.3 g); 2% milk, 1 cup (244 g): leucine 0.76 g, isoleucine 0.42 g, valine 0.53 g (total about 1.7 g); Cooked lentils, 1 cup (198 g): leucine 1.29 g, isoleucine 0.77 g, valine 0.89 g (total about 3.0 g); Raw firm tofu (calcium sulfate), half cup (126 g): leucine 1.75 g, isoleucine 1.07 g, valine 1.1 g (total about 3.9 g); Dry-roasted peanuts, 1 oz (28.35 g): leucine 0.44 g, isoleucine 0.24 g, valine 0.28 g (total about 1.0 g).
2 high certainty4 low certainty3 very low certainty
What was looked at
The 9 benefits and uses checked for BCAAs (leucine, isoleucine, valine), each with how strong the evidence is. Tap one to open it.
- Essential building blocks of proteinHigh certainty
- Food sourcesHigh certainty
- Muscle soreness after hard exerciseLow certainty
- Muscle strength and size in older adultsLow certainty
- Performance and body build in athletesLow certainty
- Hepatic encephalopathy in cirrhosis (medical setting)Low certainty
- Survival in cirrhosisVery low certainty
- Quality of life and nutrition markers in cirrhosisVery low certainty
- Blood BCAA levels and type 2 diabetesVery low certainty
Lab markers tracked in the studies
Muscle soreness ratingMuscle strength (such as handgrip)Muscle massHepatic encephalopathy not improvedDeath from any causeBlood albuminBlood BCAA level
What is BCAAs (leucine, isoleucine, valine) good for?
The main studied uses and how strong the human evidence is for each. Most trials are small to medium and differ a lot, so none of the results is strong.
Benefits, one by one
Each card is a research question, not a promise. Tap a goal to filter. Open a card to see the studies, doses and limits.
Essential building blocks of protein
High certaintyLeucine, isoleucine and valine are three of the nine essential amino acids. The body cannot make them, so they must come from food. They are used to make proteins and can also be used for energy.
1 studiesFrom food protein and from supplements; forms are not compared here.
Studies, doses and limits
What the trials found
MedlinePlus lists histidine, isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan and valine as the 9 essential amino acids. It says a balance of amino acids over the whole day matters, and that a diet based on a single plant item is not enough. No trial was read showing extra BCAAs help people who already eat enough protein.
Results
Their role is established. Extra BCAA powders are not shown to add benefit for people who already eat enough protein.
Effect sizes as reported
No effect sizes apply: these are nutrient roles, not trial results.
Why this rating
High that these are essential amino acids with a normal role in the body (MedlinePlus). This is not a trial result for any supplement.
Form and dose studied
From food protein and from supplements; forms are not compared here.
Who was studied
General population.
Limits
A general information page, not a trial.
Why researchers looked
People ask whether they get enough protein and whether extra amino acid powders add anything.
Traditional use
Amino acids are a basic part of food protein. Their normal role is well established; that is different from showing that extra powders help.
Proposed mechanism Established nutrition
Amino acids join together to make proteins. MedlinePlus says the body uses them to grow, repair tissue and do other jobs, and can use them for energy.
A proposed mechanism does not show that the effect happens in people.
A few people cannot break these amino acids down; see the Safety tab.
Food sources
High certaintyBCAAs come with the protein in meat, fish, eggs, dairy, soy and legumes. Protein-rich animal foods have the most per portion; tofu and lentils also give a good amount.
2 studiesNutrient content per household portion.
Studies, doses and limits
What the trials found
USDA values for leucine, isoleucine and valine together (SR Legacy, April 2018): Chicken breast, roasted, 1 cup chopped (140 g): leucine 3.26 g, isoleucine 2.29 g, valine 2.15 g (total about 7.7 g); Ground beef patty (85% lean), broiled, 3 oz (85 g): leucine 1.23 g, isoleucine 0.7 g, valine 0.78 g (total about 2.7 g); Farmed Atlantic salmon, cooked, 3 oz (85 g): leucine 1.53 g, isoleucine 0.87 g, valine 0.97 g (total about 3.4 g); Hard-boiled egg, 1 large (50 g): leucine 0.54 g, isoleucine 0.34 g, valine 0.38 g (total about 1.3 g); 2% milk, 1 cup (244 g): leucine 0.76 g, isoleucine 0.42 g, valine 0.53 g (total about 1.7 g); Cooked lentils, 1 cup (198 g): leucine 1.29 g, isoleucine 0.77 g, valine 0.89 g (total about 3.0 g); Raw firm tofu (calcium sulfate), half cup (126 g): leucine 1.75 g, isoleucine 1.07 g, valine 1.1 g (total about 3.9 g); Dry-roasted peanuts, 1 oz (28.35 g): leucine 0.44 g, isoleucine 0.24 g, valine 0.28 g (total about 1.0 g). MedlinePlus Genetics names milk, meat and eggs as protein-rich foods that contain all three. These are nutrient contents, not advice on how much to eat.
Results
Ordinary protein foods supply all three BCAAs. Food and pills are not the same: food also brings other amino acids and nutrients, and no trial compared them.
Effect sizes as reported
Nutrient contents, not trial effects.
Why this rating
High for the food values (USDA data tables). No trial compared food BCAAs with supplements.
Form and dose studied
Nutrient content per household portion.
Who was studied
General population.
Limits
Values are for the specific USDA food entries listed; brands and recipes vary. Totals are rounded sums of the three amino acids.
Why researchers looked
Many people ask whether food already supplies BCAAs.
Traditional use
Food protein has always been the source of these amino acids.
Proposed mechanism Established nutrition
Protein is digested into amino acids, including leucine, isoleucine and valine.
A proposed mechanism does not show that the effect happens in people.
None specific for amounts found in food.
Muscle soreness after hard exercise
Low certaintySeveral trials found less muscle soreness 1 to 3 days after damaging exercise when people took BCAAs. It seemed to help mainly trained people. Less soreness is not the same as better performance.
2 studiesBCAA supplements; amounts varied between trials.
Studies, doses and limits
What the trials found
A 2021 review of 10 randomised trials (9 in the meta-analysis) in healthy people found 7 studies with less soreness 24 to 72 hours after muscle-damaging exercise. The authors say this held for trained people after mild to moderate damage. A 2022 review of athlete studies also found less soreness in resistance-trained people.
Results
Less soreness in 7 of 10 trials, mainly in trained people. Unknown in untrained people.
Effect sizes as reported
Pooled size is not given in the abstract.
Why this rating
Low because trials differed a lot in training level, amount, timing and how much the exercise damaged muscle; only abstracts were read.
Form and dose studied
BCAA supplements; amounts varied between trials.
Who was studied
Healthy, mostly trained adults after one hard session.
Limits
Soreness is a feeling people report, and the reviews could not say which timing or amount works.
Why researchers looked
BCAAs are taken around hard workouts in the hope of faster recovery.
Traditional use
A sports-nutrition idea, not a traditional use.
Proposed mechanism Hypothesis
Proposed: BCAAs support muscle repair signals. This is a hypothesis; the reviews read do not prove it.
A proposed mechanism does not show that the effect happens in people.
Side effects were not reported in the abstracts.
Muscle strength and size in older adults
Low certaintyIn older people, BCAA-rich supplements gave small gains in strength, muscle mass and physical performance across 35 trials. The trials differed a lot, so the result needs caution.
1 studiesBCAA-rich supplements and essential amino acid mixtures; not BCAAs al…
Studies, doses and limits
What the trials found
A 2022 meta-analysis of 35 randomised trials found small gains over comparison groups: strength SMD 0.35 (95% CI 0.15 to 0.55), muscle mass SMD 0.25 (0.10 to 0.40), physical performance SMD 0.29 (0.00 to 0.57, P = 0.05). Essential amino acid supplements improved handgrip more than whey protein.
Results
Small gains, with large differences between trials. The supplements were BCAA-rich mixtures, not always BCAAs alone.
Effect sizes as reported
SMD 0.35 strength; 0.25 muscle mass; 0.29 physical performance.
Why this rating
Low because of high differences between trials and some risk of bias in 14 of 35 trials; the supplements were mixtures.
Form and dose studied
BCAA-rich supplements and essential amino acid mixtures; not BCAAs alone in every trial.
Who was studied
Older adults.
Limits
Mixtures make it hard to credit BCAAs alone. Only the abstract was read.
Why researchers looked
Older people can lose muscle (sarcopenia), and amino acids are tested as a way to slow this.
Traditional use
A modern nutrition research topic.
Proposed mechanism Hypothesis
Leucine is proposed to switch on muscle-building signals. Hypothesis in this review.
A proposed mechanism does not show that the effect happens in people.
Not reported in the abstract.
Performance and body build in athletes
Low certaintyIn a review of 24 athlete studies, BCAAs tended to switch on muscle-building signals, but the effects on performance and body composition were negligible. Endurance sport results were inconsistent.
1 studiesOral BCAAs; protocols varied.
Studies, doses and limits
What the trials found
A 2022 systematic review of 24 studies in athletes and regular trainers found negligible benefit for performance and body composition. Most studies did not report total daily protein, so the effect of BCAAs is hard to separate from the rest of the diet.
Results
Little to no benefit for performance or body composition; some benefit for soreness in resistance-trained people.
Effect sizes as reported
No pooled numbers in the abstract.
Why this rating
Low because protocols differed greatly and total protein intake was usually not reported.
Form and dose studied
Oral BCAAs; protocols varied.
Who was studied
Athletes and regular trainers.
Limits
Only abstract read; protocols and diets differ.
Why researchers looked
Athletes use BCAAs hoping for better training results.
Traditional use
A sports-nutrition practice.
Proposed mechanism Hypothesis
BCAAs are oxidised in muscle and may stimulate muscle-building signals (stated in the review); this did not translate into clear performance gains.
A proposed mechanism does not show that the effect happens in people.
Not reported in the abstract.
Hepatic encephalopathy in cirrhosis (medical setting)
Low certaintyIn people with cirrhosis, BCAAs may reduce hepatic encephalopathy, a brain problem caused by liver failure. The evidence is low-certainty and this was studied under medical care, not as self-treatment.
1 studiesOral (10 trials) and intravenous (8 trials) BCAAs.
Studies, doses and limits
What the trials found
A 2026 Cochrane review of 18 randomised trials in 934 adults (almost all with cirrhosis; 10 trials used oral BCAAs and 8 intravenous) found BCAAs probably reduce hepatic encephalopathy: risk ratio 0.79 (95% CI 0.64 to 0.96), low-certainty evidence. No trials were done in children.
Results
A small benefit for hepatic encephalopathy in adults with cirrhosis; low certainty.
Effect sizes as reported
RR 0.79 for hepatic encephalopathy that did not improve.
Why this rating
Low because of risk of bias, indirectness and imprecision (rated by the Cochrane authors); comparison groups were mostly diets.
Form and dose studied
Oral (10 trials) and intravenous (8 trials) BCAAs.
Who was studied
Adults with cirrhosis and overt or covert hepatic encephalopathy.
Limits
Control groups were diets, lactulose or neomycin; no trials compared with rifaximin. Three trials were industry-supported.
Why researchers looked
In liver failure, the balance of amino acids in the blood changes, and BCAAs have been tested for many years.
Traditional use
A clinical nutrition use, studied in hospitals and clinics.
Proposed mechanism Not established
Not established. The abstract describes the condition but does not give a mechanism.
A proposed mechanism does not show that the effect happens in people.
Nausea and diarrhoea were recorded more often; very uncertain. Only a doctor should decide on this use.
Survival in cirrhosis
Very low certaintyThe same Cochrane review could not say whether BCAAs change the chance of dying. The result was close to no effect and very uncertain.
1 studiesOral and intravenous BCAAs.
Studies, doses and limits
What the trials found
Across 17 trials with 867 people, death from any cause had RR 0.89 (95% CI 0.71 to 1.12), rated very low-certainty evidence.
Results
No clear effect on survival.
Effect sizes as reported
RR 0.89
Why this rating
Very low certainty (Cochrane rating), with wide confidence intervals including no effect.
Form and dose studied
Oral and intravenous BCAAs.
Who was studied
Adults with cirrhosis and hepatic encephalopathy.
Limits
Only the abstract was read.
Why researchers looked
The important question is whether any treatment helps people live longer.
Traditional use
A clinical outcome.
Proposed mechanism Not applicable
Not applicable: this is a trial outcome.
A proposed mechanism does not show that the effect happens in people.
None specific.
Quality of life and nutrition markers in cirrhosis
Very low certaintyThe Cochrane review found no clear effect of BCAAs on quality of life, blood albumin or nitrogen balance. The evidence for these outcomes is very uncertain.
1 studiesOral and intravenous BCAAs.
Studies, doses and limits
What the trials found
Three trials gave quality of life data; none found benefit or harm on the SF-36 score among people with hepatic encephalopathy. Albumin: mean difference 0.60 (95% CI -0.90 to 2.09; 3 trials, 176 people). Nitrogen balance: SMD 0.82 (-1.01 to 2.64; 3 trials, 108 people). Both were very low-certainty.
Results
No clear effect.
Effect sizes as reported
Albumin MD 0.60; nitrogen balance SMD 0.82.
Why this rating
Very low certainty (Cochrane rating); few small trials.
Form and dose studied
Oral and intravenous BCAAs.
Who was studied
Adults with cirrhosis.
Limits
Quality of life scores could not be pooled.
Why researchers looked
People with cirrhosis often become undernourished, so trials looked at nutrition markers.
Traditional use
A clinical outcome.
Proposed mechanism Not applicable
Not applicable: these are trial outcomes.
A proposed mechanism does not show that the effect happens in people.
None specific.
Blood BCAA levels and type 2 diabetes
Very low certaintyPeople with higher blood levels of BCAAs were more likely to develop type 2 diabetes later. This is a link in blood levels. It does not show that BCAAs from food or supplements cause diabetes.
1 studiesNot an intervention.
Studies, doses and limits
What the trials found
A 2022 meta-analysis of 9 observational studies found higher blood levels of valine (OR 2.08, 95% CI 2.04 to 2.12), leucine (OR 2.25, 1.76 to 2.87) and isoleucine (OR 2.12, 2.00 to 2.25) linked to later diagnosis of type 2 diabetes, across follow-up of under 6, 6 to 12 and 12 or more years.
Results
Higher blood BCAAs go with higher diabetes risk. No trial of BCAA supplements and diabetes was read.
Effect sizes as reported
OR about 2.1 to 2.3
Why this rating
Observational evidence about blood levels, not supplements; very low for any claim about supplements.
Form and dose studied
Not an intervention.
Who was studied
Adults followed in 9 observational studies.
Limits
Blood levels reflect body weight and insulin resistance; no cause is shown.
Why researchers looked
Researchers look for early warning signs of diabetes in the blood.
Traditional use
A research finding, not a use.
Proposed mechanism Association
Not established. The abstract suggests BCAAs as an early marker, not a cause.
A proposed mechanism does not show that the effect happens in people.
People with diabetes should ask their doctor before using amino acid supplements.
Connections to the rest of health
How BCAAs (leucine, isoleucine, valine) connects to the rest of our health knowledge graph. Every link says what kind of connection it is. A safety link (for example to the liver) is a warning, not a benefit. A study that merely mentions a topic never creates a benefit link.
Explore every connection: goals, body systems, organs, symptoms, genes
A. Wellness goals
| Connected to | Kind of connection | Evidence status | Context | Studies |
|---|---|---|---|---|
| Balanced Nutrition | High certainty | Essential building blocks of protein: Leucine, isoleucine and valine are three of the nine essential amino acids. The body cannot make them, so they must come from food. They are used to make proteins and can also be used for energy. | 7 | |
| Balanced Nutrition | High certainty | Food sources: BCAAs come with the protein in meat, fish, eggs, dairy, soy and legumes. Protein-rich animal foods have the most per portion; tofu and lentils also give a good amount. | 11 8 | |
| Muscle Recovery | Low certainty | Muscle soreness after hard exercise: Several trials found less muscle soreness 1 to 3 days after damaging exercise when people took BCAAs. It seemed to help mainly trained people. Less soreness is not the same as better performance. | 12 6 | |
| Recovery Optimization | Low certainty | Muscle soreness after hard exercise: Several trials found less muscle soreness 1 to 3 days after damaging exercise when people took BCAAs. It seemed to help mainly trained people. Less soreness is not the same as better performance. Performance and body build in athletes: In a review of 24 athlete studies, BCAAs tended to switch on muscle-building signals, but the effects on performance and body composition were negligible. Endurance sport results were inconsistent. | 12 6 | |
| Healthy Aging | Low certainty | Muscle strength and size in older adults: In older people, BCAA-rich supplements gave small gains in strength, muscle mass and physical performance across 35 trials. The trials differed a lot, so the result needs caution. | 2 |
B. Body systems
| Connected to | Kind of connection | Evidence status | Context | Studies |
|---|---|---|---|---|
| Whole Body | Biological association | High certainty | Studied for: Essential building blocks of protein Studied for: Food sources | 7 11 8 |
| Musculoskeletal System | Biological association | High certainty | Studied for: Essential building blocks of protein Studied for: Muscle soreness after hard exercise | 7 12 6 2 |
| Hepatic System | Biological association | Low certainty | Studied for: Hepatic encephalopathy in cirrhosis (medical setting) Studied for: Survival in cirrhosis | 1 |
| Nervous System | Biological association | Low certainty | Studied for: Hepatic encephalopathy in cirrhosis (medical setting) | 1 |
| Metabolism Weight | Biological association | Very low certainty | Studied for: Blood BCAA levels and type 2 diabetes | 10 |
E. Health conditions
| Connected to | Kind of connection | Evidence status | Context | Studies |
|---|---|---|---|---|
| Maple syrup urine disease | Documented risk | Leucine, isoleucine and valine build up and are toxic in this inherited condition. Preparation or compound: BCAA products |
8 | |
| Hepatic encephalopathy | Low certainty trial evidence | Probably fewer people with persisting hepatic encephalopathy in cirrhosis trials; low certainty. Preparation or compound: Oral or intravenous BCAAs |
1 | |
| Hepatic encephalopathy | Preliminary | BCAAs probably reduced persisting hepatic encephalopathy in cirrhosis trials; low certainty. Preparation or compound: Oral or intravenous BCAAs |
1 | |
| Sarcopenia | Preliminary | Small gains in strength and muscle mass in older adults; large differences between trials. Preparation or compound: BCAA-rich supplements |
2 |
I. Biomarkers
| Connected to | Kind of connection | Evidence status | Context | Studies |
|---|---|---|---|---|
| Muscle soreness rating | Biological association | Low certainty | Measured in trials: lower in 7 of 10 trials. A lab change is not the same as a health benefit. | 12 |
| Muscle strength (such as handgrip) | Biological association | Low certainty | Measured in trials: higher (small). A lab change is not the same as a health benefit. | 2 |
| Muscle mass | Biological association | Low certainty | Measured in trials: higher (small). A lab change is not the same as a health benefit. | 2 |
| Hepatic encephalopathy not improved | Biological association | Low certainty | Measured in trials: fewer people not improved. A lab change is not the same as a health benefit. | 1 |
| Death from any cause | Biological association | Very low certainty | Measured in trials: no clear change. A lab change is not the same as a health benefit. | 1 |
| Blood albumin | Biological association | Very low certainty | Measured in trials: no clear change. A lab change is not the same as a health benefit. | 1 |
| Blood BCAA level | Biological association | Very low certainty | Measured in trials: higher levels linked to more diabetes. A lab change is not the same as a health benefit. | 10 |
J. Genes, receptors and enzymes
| Connected to | Kind of connection | Evidence status | Context | Studies |
|---|---|---|---|---|
| BCKDHA, BCKDHB, DBT | Preliminary mechanism | Human | Genes for the complex that breaks down BCAAs; changes cause maple syrup urine disease. | 8 |
K. Biological pathways
| Connected to | Kind of connection | Evidence status | Context | Studies |
|---|---|---|---|---|
| Levodopa | Preliminary mechanism | Human | Competes with BCAAs for transport. | 9 |
L. Active compounds
| Connected to | Kind of connection | Evidence status | Context | Studies |
|---|---|---|---|---|
| L-leucine | Biological association | Human | Most studied of the three for muscle-building signals; short-term studies suggest blood ammonia rises at very high intakes. | 4 6 |
| L-isoleucine | Biological association | Human | Essential amino acid; built up in maple syrup urine disease. | 7 8 |
| L-valine | Biological association | Human | Essential amino acid; built up in maple syrup urine disease. | 7 8 |
Each connection is stored with the ingredient, the connected record, the kind of connection, the evidence status, the supporting studies, the preparation or compound involved, and a review date (last reviewed October 26, 2026).
Evidence at a glance: what the research found for 9 outcomes
Each outcome below is one thing researchers measured. Certainty is how far the evidence can be trusted, not how well it works. The full studies are on the next tab.
The evidence
The research centre for BCAAs (leucine, isoleucine, valine). Every record here was checked against PubMed or the publisher's page; we never list a study we have not verified.
Evidence by outcome
Bars show how many studies we found for each outcome, not how well it works. People are added up across trials only (reviews are not added, to avoid double counting).
How we rate evidence
High certainty
Several well-run trials or reviews agree; further research is unlikely to change the picture much.
Moderate certainty
Good trials point the same way, but some doubt remains.
Low certainty
Small, short or inconsistent trials. The finding could change with better research.
Very low certainty
Very little or very weak human data. Treat as a possibility only.
Mixed findings
Trials or reviews disagree with each other.
Not enough evidence
Not enough human research to say either way.
Evidence against
Good research found no benefit, or found harm.
We take the reviewers' own risk-of-bias and GRADE statements where they exist, and otherwise judge from study size, design, consistency, directness and whether a product matches what is sold. Many publications do not make evidence high. Method note: We started from our existing BCAA summary, read MedlinePlus and MedlinePlus Genetics pages, re-checked food values in saved USDA FoodData Central data, and re-read PubMed abstracts for reviews. Only abstracts were read for studies. Agency sites for upper limits (NIH Office of Dietary Supplements, EFSA) were not checked.
Study library: every study we checked 12
| Study | Design | People | Product, dose, length | Result |
|---|---|---|---|---|
| Aamann 2026 Branched-chain amino acids for people with cirrhosis and hepatic encephalopathy. Cochrane Database Syst Rev · PMID 41542879 · DOI |
Systematic review meta analysis |
934 18 randomised trials in 934 adults, almost all with cirrhosis; 13 with overt and 5 with covert hepatic encephalopathy; no trials in children |
BCAAs (10 trials oral, 8 intravenous) Oral or intravenous amino acids Varied Four days to two years · vs No intervention or placebo (2 trials), diets (11), lactulose (3), neomycin (2) |
BCAAs probably reduce hepatic encephalopathy (low-certainty evidence). The effect on death from any cause is very uncertain. Nausea and diarrhoea were recorded in 12% with BCAAs and 3% with diet controls, but the evidence is very uncertain. No clear effect on quality of life, albumin or nitrogen balance (very low certainty). Three trials were industry-supported. Hepatic encephalopathy RR 0.79; death RR 0.89; nausea and diarrhoea RR 2.05; albumin MD 0.60; nitrogen balance SMD 0.82 (Hepatic encephalopathy 0.64 to 0.96 (18 trials, 934 people); death 0.71 to 1.12 (17 trials, 867); nausea/diarrhoea 0.40 to 10.58 (6 trials, 1,015); albumin -0.90 to 2.09; nitrogen balance -1.01 to 2.64) Methods, limits and fundingOutcomes: Death from any cause, hepatic encephalopathy, nausea and diarrhoea, quality of life, albumin, nitrogen balance Limitations: Most evidence is low or very low certainty (risk of bias, indirectness, imprecision). Control groups were mostly diets, not the usual drugs, and no trials compared with rifaximin. Three trials are ongoing. Only abstract read. Funding and conflicts: Review itself: no funding. Three included trials received interventions from for-profit organisations. Read: abstract |
| Bai 2022 Effects of branched-chain amino acid-rich supplementation on EWGSOP2 criteria for sarcopenia in older adults: a systematic review and meta-analysis. Eur J Nutr · PMID 34705076 · DOI |
Systematic review meta analysis |
35 randomised trials of BCAA-rich supplements in older people | BCAA-rich supplements (some trials used essential amino acid mixtures or whey as comparison groups) Oral or intravenous amino acids Varied Varied · vs Control groups (some whey protein) |
BCAA-rich supplements gave small gains in muscle strength, muscle mass and physical performance. Essential amino acid supplements improved handgrip strength more than whey protein. The authors warn that trials differed a lot and results need caution. Strength SMD 0.35; muscle mass SMD 0.25; physical performance SMD 0.29 (P = 0.05). (Strength 0.15 to 0.55; muscle mass 0.10 to 0.40; physical performance 0.00 to 0.57) Methods, limits and fundingOutcomes: Muscle strength, muscle mass, physical performance Limitations: High differences between trials. 14 of 35 trials had some potential bias. Supplements were BCAA-rich mixtures, not always BCAAs alone. Only abstract read. Funding and conflicts: Not stated in the abstract. Read: abstract |
| Cynober 2016 Proposals for Upper Limits of Safe Intake for Arginine and Tryptophan in Young Adults and an Upper Limit of Safe Intake for Leucine in the Elderly. J Nutr · PMID 27934658 · DOI |
Narrative review |
Workshop-based proposals for older adults (leucine) and young adults (arginine, tryptophan) | Leucine Leucine Proposed upper limit of safe intake for leucine in older people: 500 mg/kg/day |
A workshop proposed an upper limit of safe intake of total dietary leucine for older people. It applies only to high-quality products that meet US Pharmacopeia specifications. Proposed leucine limit for the elderly 500 mg/kg/day (Not applicable) Methods, limits and fundingOutcomes: Upper limit of safe intake Limitations: A proposal from a workshop, not an official regulator limit. Does not cover isoleucine or valine. Only abstract read. Funding and conflicts: Not stated in the abstract. Read: abstract |
| Elango 2016 Safety and Tolerability of Leucine Supplementation in Elderly Men. J Nutr · PMID 27934655 · DOI |
Narrative review |
Two short-term dose-response studies of leucine in young men and older men (about 72 years) | Leucine alone Leucine Increasing leucine intakes in the studies (see abstract) Acute diet studies · vs Lower leucine intakes |
Leucine oxidation rose with intake then levelled off at about 550 mg/kg/day in young men and 431 mg/kg/day in older men. Blood ammonia rose above the normal value (35 micromol/L) at leucine intakes above 550 mg/kg/day. The authors say the studies were short-term and that long-term studies with more markers are needed. Break point: 550 mg/kg/day (young men); 431 mg/kg/day (older men) (Young men 454 to 646; older men 351 to 511 mg/kg/day) Methods, limits and fundingOutcomes: Leucine oxidation and blood ammonia Limitations: Short-term acute studies in healthy men only; not long-term use; leucine alone, not all three BCAAs. Only abstract read. Funding and conflicts: Not stated in the abstract. Research on upper limits for amino acids was done under an initiative of the International Council on Amino Acid Science, a nonprofit organisation; its links to the supplement industry are not described in the abstract. Read: abstract |
| Elango 2023 Tolerable Upper Intake Level for Individual Amino Acids in Humans: A Narrative Review of Recent Clinical Studies. Adv Nutr · PMID 37062432 · DOI |
Narrative review |
Review of recent dose-response studies in relatively healthy adults for 10 amino acids, including leucine | Individual amino acids (here, leucine) Leucine Researcher-proposed limits in the review: leucine 35 g/day in young adults and 30 g/day in older adults Acute studies |
The review says no national health agency has set upper intake levels for amino acids because of a lack of dose-response trials. It offers research-based first estimates, including for leucine in young and older adults. The review does not give limits for isoleucine or valine. Leucine proposed limits: 35 g/day (young), 30 g/day (older) (Not given in the abstract) Methods, limits and fundingOutcomes: Tolerable upper intake levels Limitations: Proposals by one researcher's group, not an official limit; based on short-term studies in healthy adults, not people with illness or long-term users. Only abstract read. Funding and conflicts: Not stated in the abstract. The studies were done under the International Council on Amino Acid Science initiative (a nonprofit organisation); links to industry are not described in the abstract. Read: abstract |
| Martinho 2022 Oral Branched-Chain Amino Acids Supplementation in Athletes: A Systematic Review. Nutrients · PMID 36235655 · DOI |
Systematic review |
24 studies in athletes and people who train regularly (2,298 records screened) | Oral BCAAs Oral or intravenous amino acids Protocols differed a lot between studies Varied · vs Varied |
BCAAs tended to switch on muscle-building signals, but benefits for performance and body composition were negligible. In resistance-trained people, BCAAs lessened muscle soreness after exercise. In endurance sport the findings were inconsistent. No pooled numbers in the abstract. (Not given.) Methods, limits and fundingOutcomes: Performance, body composition, muscle soreness Limitations: Protocols differed a lot, and most studies did not report total daily protein, so BCAA effects are hard to separate from the rest of the diet. Only abstract read. Funding and conflicts: Not stated in the abstract. Read: abstract |
| MedlinePlus (US National Library of Medicine) 2025 Amino acids MedlinePlus (US National Library of Medicine) · Source |
Authoritative guidance |
Not applicable | Not applicable |
Says amino acids build proteins and can be used for energy. Lists the 9 essential amino acids, which the body cannot make: histidine, isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan and valine. Says a balance of amino acids over the whole day matters. Page review date 21 January 2025. Not applicable (Not applicable) Methods, limits and fundingOutcomes: Background facts Limitations: A general information page, not a trial. Funding and conflicts: Public information service; no product is promoted. Read: page |
| MedlinePlus Genetics (US National Library of Medicine) 2017 Maple syrup urine disease MedlinePlus Genetics (US National Library of Medicine) · Source |
Authoritative guidance |
Not applicable | Not applicable |
Inherited disorder in which the body cannot break down leucine, isoleucine and valine. They and their by-products build up and, the page says, are toxic to the brain and other organs. Signs include sweet-smelling urine, poor feeding, vomiting, lethargy, abnormal movements and delayed development; untreated it can lead to seizures, coma and death. About 1 in 185,000 infants worldwide. The page text read gave no clear review date; the year 2017 comes from our earlier summary. Not applicable (Not applicable) Methods, limits and fundingOutcomes: Background facts Limitations: A general information page, not a trial. Funding and conflicts: Public information service; no product is promoted. Read: page |
| Müller 2024 Therapeutic drug monitoring in Parkinson's disease. J Neural Transm (Vienna) · PMID 39227478 · DOI |
Narrative review |
Review of drug monitoring in Parkinson's disease | Levodopa (a medicine), with its amino acid competitors Mechanism statement |
The review says levodopa and a related chemical compete with other aromatic amino acids and with branched-chain amino acids for the limited transport capacity in the gut and at the blood-brain barrier. It says little is known about plasma levels with different drug combinations. Not applicable (Not applicable) Methods, limits and fundingOutcomes: Levodopa blood levels Limitations: A narrative review about drug monitoring; it does not test BCAA supplements. The competition is stated as a mechanism, not shown in a supplement trial. Only abstract read. Funding and conflicts: Research support from non-US government bodies is listed; no industry funding is stated in the abstract. Read: abstract |
| Ramzan 2022 The Association between Circulating Branched Chain Amino Acids and the Temporal Risk of Developing Type 2 Diabetes Mellitus: A Systematic Review & Meta-Analysis. Nutrients · PMID 36297095 · DOI |
Systematic review meta analysis |
9 observational studies; blood BCAA levels measured before type 2 diabetes was diagnosed | Not an intervention: blood levels of valine, leucine and isoleucine Blood levels (observational) Follow-up 0 to 6, 6 to 12 and 12 or more years · vs Lower blood BCAA levels |
Higher blood levels of all three BCAAs were linked to later type 2 diabetes at every follow-up length. This is a link in blood levels, not proof that eating or supplementing BCAAs causes diabetes. Odds ratios: valine 2.08, leucine 2.25, isoleucine 2.12 (Valine 2.04 to 2.12; leucine 1.76 to 2.87; isoleucine 2.00 to 2.25) Methods, limits and fundingOutcomes: Later diagnosis of type 2 diabetes Limitations: Observational; blood levels reflect many things (body weight, insulin resistance). Authors suggest use as an early marker, not a cause. Only abstract read. Funding and conflicts: Not stated in the abstract. Read: abstract |
| US Department of Agriculture 2018 USDA FoodData Central, SR Legacy (April 2018 release) US Department of Agriculture · Source |
Authoritative guidance |
Not applicable | Not applicable |
Amino acid values per 100 g and per household portion read from a saved local copy of the SR Legacy tables: Chicken breast, roasted, 1 cup chopped (140 g): leucine 3.26 g, isoleucine 2.29 g, valine 2.15 g (total about 7.7 g); Ground beef patty (85% lean), broiled, 3 oz (85 g): leucine 1.23 g, isoleucine 0.7 g, valine 0.78 g (total about 2.7 g); Farmed Atlantic salmon, cooked, 3 oz (85 g): leucine 1.53 g, isoleucine 0.87 g, valine 0.97 g (total about 3.4 g); Hard-boiled egg, 1 large (50 g): leucine 0.54 g, isoleucine 0.34 g, valine 0.38 g (total about 1.3 g); 2% milk, 1 cup (244 g): leucine 0.76 g, isoleucine 0.42 g, valine 0.53 g (total about 1.7 g); Cooked lentils, 1 cup (198 g): leucine 1.29 g, isoleucine 0.77 g, valine 0.89 g (total about 3.0 g); Raw firm tofu (calcium sulfate), half cup (126 g): leucine 1.75 g, isoleucine 1.07 g, valine 1.1 g (total about 3.9 g); Dry-roasted peanuts, 1 oz (28.35 g): leucine 0.44 g, isoleucine 0.24 g, valine 0.28 g (total about 1.0 g). Portion values are the per-100 g values scaled by portion weight. Not applicable (Not applicable) Methods, limits and fundingOutcomes: Background facts Limitations: A general information page, not a trial. Funding and conflicts: Public information service; no product is promoted. Read: data table |
| Weber 2021 The use of BCAA to decrease delayed-onset muscle soreness after a single bout of exercise: a systematic review and meta-analysis. Amino Acids · PMID 34669012 · DOI |
Systematic review meta analysis |
10 randomised trials in the review (9 in the meta-analysis) in healthy people after one session of muscle-damaging exercise | BCAA supplements Oral or intravenous amino acids Doses up to 255 mg/kg/day were linked to less soreness in trained people (as stated in the abstract) Varied between trials · vs Placebo or no BCAA |
Seven studies found BCAA reduced soreness 24 to 72 hours later. The authors say it helped trained people, at lower amounts, after mild to moderate muscle damage. They could not say whether it works in untrained people, or at higher amounts, because trials differed a lot. Pooled numbers are not given in the abstract. (Not given in the abstract.) Methods, limits and fundingOutcomes: Delayed-onset muscle soreness 24 to 72 hours after exercise Limitations: Large differences between trials in training status, amount, timing and how much damage the exercise caused. Only abstract read. Funding and conflicts: Not stated in the abstract. Read: abstract |
What we do not know yet
- No trial was read showing that extra BCAAs help people who already eat enough protein.
- No official upper intake limit was found; agency sites were not checked.
- Pregnancy, breastfeeding and children were not covered by the sources read.
- Contamination and label accuracy of BCAA products were not researched.
- BCAAs and ALS, kidney disease and long-term use were not researched.
- Uses such as sleep, mood, fatigue and weight loss were not researched here.
How new research is added
New studies are found by a saved PubMed search and placed in a review queue before the page changes.
Lab markers
What changed in blood or saliva tests during trials. A changed number is not the same as feeling or being healthier, and we give no "normal ranges".
Other 7
Muscle soreness rating
Lower in 7 of 10 trials in trials
How sore muscles feel 1 to 3 days after hard exercise, usually rated by the person.
Low certaintyResults and what it means
Why it was measured
To see whether BCAAs lessen soreness after muscle-damaging exercise.
Statistical vs. clinical meaning
Self-rated and varied between trials.
Safety implication
None reported in the abstract.
| Study | Result | People | Product |
|---|---|---|---|
| 12 | 7 of 10 randomised trials found less soreness 24 to 72 hours after exercise | Healthy people, mostly trained | BCAA supplements |
Muscle strength (such as handgrip)
Higher (small) in trials
How hard a person can squeeze or lift, measured with a device.
Low certaintyResults and what it means
Why it was measured
A key sign of muscle loss in older age.
Statistical vs. clinical meaning
Small gain; large differences between trials.
Safety implication
None reported in the abstract.
| Study | Result | People | Product |
|---|---|---|---|
| 2 | SMD 0.35 (95% CI 0.15 to 0.55) for strength | 35 trials in older adults | BCAA-rich supplements |
Muscle mass
Higher (small) in trials
The amount of muscle tissue in the body.
Low certaintyResults and what it means
Why it was measured
Loss of muscle mass is part of sarcopenia.
Statistical vs. clinical meaning
Small gain; mixtures were used, not always BCAAs alone.
Safety implication
None reported in the abstract.
| Study | Result | People | Product |
|---|---|---|---|
| 2 | SMD 0.25 (95% CI 0.10 to 0.40) for muscle mass | 35 trials in older adults | BCAA-rich supplements |
Hepatic encephalopathy not improved
Fewer people not improved in trials
Whether a person's brain symptoms from liver failure stayed or got worse.
Low certaintyResults and what it means
Why it was measured
The main outcome in the cirrhosis trials.
Statistical vs. clinical meaning
Probably fewer people with persisting symptoms; low certainty.
Safety implication
Nausea and diarrhoea recorded more often; very uncertain.
| Study | Result | People | Product |
|---|---|---|---|
| 1 | RR 0.79 (95% CI 0.64 to 0.96), 18 trials, 934 people | Adults with cirrhosis | Oral or intravenous BCAAs |
Death from any cause
No clear change in trials
Whether participants died during the trial.
Very low certaintyResults and what it means
Blood albumin
No clear change in trials
A blood protein that falls when the liver or nutrition is poor.
Very low certaintyBlood BCAA level
Higher levels linked to more diabetes in trials
The amount of leucine, isoleucine and valine in the blood.
Very low certaintyResults and what it means
Why it was measured
Higher levels go with later type 2 diabetes in observational studies.
Statistical vs. clinical meaning
A possible early marker, not a cause.
Safety implication
No supplement trial was read.
| Study | Result | People | Product |
|---|---|---|---|
| 10 | ORs 2.08 (valine), 2.25 (leucine), 2.12 (isoleucine) | 9 observational studies | Not an intervention |
Safety
What studies and official sources say about side effects, medicines and who should check first. Each point shows what kind of evidence it comes from.
Main points to know 4
- Do not use if you have maple syrup urine disease unless your metabolic team says so. Maple syrup urine disease (MSUD) is an inherited condition in which the body cannot break down leucine, isoleucine and valine. MedlinePlus Genetics says they and their by-products build up and are toxic to the brain and other organs, and that untreated it can lead to seizures, coma and death. BCAA supplements add exactly these three amino acids, so anyone with MSUD, or a family history of it, should ask their metabolic doctor before using any product containing them. Authoritative guidance 8
- Liver disease: BCAAs have been studied only under medical care. In the Cochrane review, BCAAs were tested in adults with cirrhosis and hepatic encephalopathy under medical supervision. Nausea and diarrhoea were recorded in 12% of people given BCAAs and 3% of those on diet controls, but the review rates this very uncertain. Nobody with liver disease should start BCAAs on their own. Meta-analysis 1
- Very high leucine intakes raised blood ammonia in short-term studies. In short-term studies in healthy men, blood ammonia rose above the normal value at leucine intakes above 550 mg per kg of body weight a day. The authors say long-term studies are needed. No national health agency has set an upper intake level for leucine, isoleucine or valine, according to a 2023 review. Narrative review 4 5
- Safety of long-term use, pregnancy, breastfeeding and children was not established in the sources read. None of the reviews read gave safety data for pregnancy, breastfeeding or children, and the cirrhosis review found no trials in children. Absence of data is not proof of safety. Ask a doctor or pharmacist first. Gap 1
Side effects 3
| Effect | How often | Severity and recovery | Evidence |
|---|---|---|---|
| Nausea and diarrhoea This was in people with cirrhosis, mostly given BCAAs by mouth or by vein under medical care; it may not apply to healthy people. | In cirrhosis trials: 58 of 477 (12%) with BCAAs versus 16 of 538 (3%) with diet controls; RR 2.05 (95% CI 0.40 to 10.58), very uncertain. | Classed as serious adverse events in the review Not stated in the abstract. | Meta-analysis 1 |
| Raised blood ammonia Acute diet studies with leucine alone. Long-term use was not studied. | Above the normal value (35 micromol/L) at leucine intakes above 550 mg/kg/day in short-term studies in healthy men. | Not stated Not stated in the abstract. | Narrative review 4 |
| Side effects in exercise and older-adult trials Absence from an abstract does not mean no side effects occurred. | Not reported in the abstracts of the soreness, older-adult and athlete reviews. | Unknown Unknown | Gap 12 2 6 |
Liver
BCAAs have been studied as a treatment in cirrhosis under medical care. No case reports of liver injury from BCAA supplements were found in the sources read. A liver-safety reference (LiverTox) was not opened for this page. 1
How often. No frequency was found.
Monitoring. No agency monitoring advice was found.
This is a safety connection. It is not evidence that BCAAs (leucine, isoleucine, valine) supports liver health.
Medicines and supplements 3
| With | Why it matters | Importance | Evidence | What to do |
|---|---|---|---|---|
| Levodopa (Parkinson's disease medicine) prescription | A 2024 review says levodopa competes with branched-chain amino acids and other amino acids for limited transport in the gut and at the blood-brain barrier. | The review states the competition but does not test BCAA supplements; the size of any effect is unknown. | Review Low certainty 9 | Ask your doctor or pharmacist before combining. |
| Diabetes medicines and insulin prescription | Blood BCAA levels are linked to later type 2 diabetes in observational studies; no interaction with diabetes medicines was found. | No source read describes an interaction. Listed because of the diabetes link only. | None found Very low certainty 10 | Ask your doctor or pharmacist if you use diabetes medicines. |
| Protein powders and other amino acid products supplement | Protein foods and powders already contain leucine, isoleucine and valine, so totals add up when products are combined. | The athlete review notes that most studies did not report total protein, so the combined intake in trials is unknown. No harm from combining was read. | Review Very low certainty 6 | Check labels for total amino acids. |
Who should check first 5
| Situation | Advice | Evidence |
|---|---|---|
| Maple syrup urine disease (inherited) | Leucine, isoleucine and valine build up and are toxic to the brain and other organs in this condition (MedlinePlus Genetics). Anyone with it should ask their metabolic team before using any product containing them. | Authoritative guidance 8 |
| Cirrhosis or other liver disease | BCAAs were studied in cirrhosis only under medical care. Ask your liver doctor before using them. | Meta-analysis 1 |
| Pregnancy and breastfeeding | No source read gave safety data for BCAA supplements in pregnancy or breastfeeding. Ask a doctor or pharmacist. | Gap |
| Children | The cirrhosis review found no trials in children. No other source on children was read. Ask a doctor. | Gap 1 |
| Parkinson's disease treated with levodopa | BCAAs compete with levodopa for transport (2024 review). Ask your doctor. | Review 9 |
Overdose, product quality and regulators
Summary. BCAAs are normal parts of food protein. Problems are seen at very high leucine intakes in short-term studies, and in people who cannot break them down (MSUD).
Animal. Not reviewed.
High dose or long term signals. Blood ammonia rose above normal at leucine intakes above 550 mg/kg/day in short-term studies in healthy men (Elango 2016). Researchers have proposed upper limits for leucine (a 2023 review proposes 35 g a day for young adults and 30 g for older adults; a 2016 workshop proposed 500 mg/kg/day for older people). These are research proposals from short-term studies, not official limits, and not advice to take that much. No limits were found for isoleucine or valine.
Overdose response. If someone has swallowed a very large amount, or has vomiting, confusion or severe drowsiness after taking amino acid products, call poison control or emergency services.
Genotoxicity. Not researched.
Contamination and label accuracy of BCAA supplements were not researched for this page.
Quality specifications. A 2016 workshop's proposed upper limit for leucine applies only to high-quality amino acid products that meet US Pharmacopeia specifications (as stated in the abstract). Whether a given product meets such specifications was not checked. 3
| Body | Action | Date |
|---|---|---|
| MedlinePlus Genetics (US National Library of Medicine) (United States) | Describes maple syrup urine disease as an inherited disorder in which leucine, isoleucine and valine cannot be broken down and build up to levels toxic to the brain and other organs. Signs include sweet-smelling urine, poor feeding, vomiting, lethargy and delayed development; untreated it can cause seizures, coma and death. source | |
| MedlinePlus (US National Library of Medicine) (United States) | Lists leucine, isoleucine and valine among the 9 essential amino acids that must come from food, and says a balance of amino acids over the whole day matters. source | 2025-01-21 |
| National health agencies (as reported by a 2023 review) (International) | The review says no national health agency has set tolerable upper intake levels for individual amino acids because dose-response trials are lacking. source | 2023-07 |
When to get medical help
- A newborn or baby with poor feeding, vomiting, unusual sleepiness or sweet-smelling urine: seek emergency care at once.
- Someone with liver disease who becomes confused, very sleepy or hard to wake: seek emergency care at once.
- Someone has swallowed a large amount of an amino acid product: call poison control or emergency services.
Stop using the product and contact a clinician or emergency service. In the US, Poison Control is 1-800-222-1222.
General information only, not medical advice. Ask a clinician or pharmacist before use, especially with medicines, in pregnancy or with a health condition. See the Natural Remedy Safety guide.
Frequently asked questions
What are BCAAs?
BCAAs are branched-chain amino acids: leucine, isoleucine and valine. They are three of the nine essential amino acids that the body cannot make and must get from food.
Which foods contain BCAAs?
All protein foods do. By USDA data a cup of roasted chicken breast has about 7.7 g of the three together, half a cup of firm tofu about 3.9 g, 3 oz of cooked salmon about 3.4 g and a cup of cooked lentils about 3.0 g.
Do BCAAs reduce muscle soreness?
Do BCAAs help athletes perform better?
A review of 24 athlete studies found negligible benefit for performance and body composition. Most studies did not report total protein intake.
Do BCAAs help older people keep muscle?
A meta-analysis of 35 trials found small gains in strength and muscle mass with BCAA-rich supplements, but trials differed a lot and often used mixtures. The evidence is low-certainty.
Are BCAAs used for liver disease?
They have been tested in cirrhosis under medical care. A 2026 Cochrane review found they probably reduce hepatic encephalopathy (low certainty), with no clear effect on survival. This is not a self-treatment.
Do BCAAs cause type 2 diabetes?
No such effect has been shown. Higher blood BCAA levels are linked to later type 2 diabetes in observational studies, but those studies cannot show cause.
Who should not use BCAA products?
What side effects are known?
In cirrhosis trials nausea and diarrhoea were recorded in 12% on BCAAs versus 3% on diet controls, but the evidence is very uncertain. Side effects were not reported in the abstracts of the exercise reviews.
Is there an official upper limit?
Do BCAAs interact with medicines?
A 2024 review says levodopa, a Parkinson's disease medicine, competes with BCAAs for transport in the gut and brain. No other interaction was found in the sources read. Ask a pharmacist.
Can BCAAs be used in pregnancy or by children?
No source read gave safety data for pregnancy, breastfeeding or children, and the cirrhosis review found no trials in children. Ask a doctor or pharmacist first.
Explore by health goal
Balanced NutritionRecovery OptimizationMuscle RecoveryHealthy Aging
Editorial transparency
- Written by
- AlternativeMed editorial team. Research compiled with AI assistance, then checked against the sources listed.
- Medical review
- None. This page has not been reviewed by a physician or pharmacist.
- First published
- 2026-10-26
- Last substantive update
- 2026-10-26
- How we research
- We started from our existing BCAA summary, read MedlinePlus and MedlinePlus Genetics pages, re-checked food values in saved USDA FoodData Central data, and re-read PubMed abstracts for reviews. Only abstracts were read for studies. Agency sites for upper limits (NIH Office of Dietary Supplements, EFSA) were not checked.
- How we rate evidence
- See "How we rate evidence" in the Evidence tab.
- Independence
- No product is promoted on this page. No affiliate links are shown. Some trials of amino acid products may have manufacturer links not stated in abstracts, and the upper-limit research was done under a nonprofit amino acid science council whose industry links are not described in the abstracts.
Sources 12
Each source was opened and checked. Where we read only the abstract, it says so. The small numbers in the text point here.
- Aamann L, Deshpande N, Dam G et al.. Branched-chain amino acids for people with cirrhosis and hepatic encephalopathy.. Cochrane Database Syst Rev. 2026. PMID 41542879. DOI 10.1002/14651858.CD001939.pub5. (abstract)
- Bai GH, Tsai MC, Tsai HW et al.. Effects of branched-chain amino acid-rich supplementation on EWGSOP2 criteria for sarcopenia in older adults: a systematic review and meta-analysis.. Eur J Nutr. 2022. PMID 34705076. DOI 10.1007/s00394-021-02710-0. (abstract)
- Cynober L, Bier DM, Kadowaki M et al.. Proposals for Upper Limits of Safe Intake for Arginine and Tryptophan in Young Adults and an Upper Limit of Safe Intake for Leucine in the Elderly.. J Nutr. 2016. PMID 27934658. DOI 10.3945/jn.115.228478. (abstract)
- Elango R, Rasmussen B, Madden K. Safety and Tolerability of Leucine Supplementation in Elderly Men.. J Nutr. 2016. PMID 27934655. DOI 10.3945/jn.116.234930. (abstract)
- Elango R. Tolerable Upper Intake Level for Individual Amino Acids in Humans: A Narrative Review of Recent Clinical Studies.. Adv Nutr. 2023. PMID 37062432. DOI 10.1016/j.advnut.2023.04.004. (abstract)
- Martinho DV, Nobari H, Faria A et al.. Oral Branched-Chain Amino Acids Supplementation in Athletes: A Systematic Review.. Nutrients. 2022. PMID 36235655. DOI 10.3390/nu14194002. (abstract)
- MedlinePlus (US National Library of Medicine). Amino acids. MedlinePlus (US National Library of Medicine). 2025. (page)
- MedlinePlus Genetics (US National Library of Medicine). Maple syrup urine disease. MedlinePlus Genetics (US National Library of Medicine). 2017. (page)
- Müller T, Gerlach M, Hefner G et al.. Therapeutic drug monitoring in Parkinson's disease.. J Neural Transm (Vienna). 2024. PMID 39227478. DOI 10.1007/s00702-024-02828-5. (abstract)
- Ramzan I, Ardavani A, Vanweert F et al.. The Association between Circulating Branched Chain Amino Acids and the Temporal Risk of Developing Type 2 Diabetes Mellitus: A Systematic Review & Meta-Analysis.. Nutrients. 2022. PMID 36297095. DOI 10.3390/nu14204411. (abstract)
- US Department of Agriculture. USDA FoodData Central, SR Legacy (April 2018 release). US Department of Agriculture. 2018. (data table)
- Weber MG, Dias SS, de Angelis TR et al.. The use of BCAA to decrease delayed-onset muscle soreness after a single bout of exercise: a systematic review and meta-analysis.. Amino Acids. 2021. PMID 34669012. DOI 10.1007/s00726-021-03089-2. (abstract)
Where to buy
Check the label first. Whatever you buy, look for these:
- The amount of the active ingredient per serving, not just the front-label claim
- A third-party testing mark (USP, NSF or ConsumerLab)
- Other ingredients and allergens
- Ask a pharmacist about interactions with your medicines
Talk to a pharmacist or doctor before you start any supplement, especially if you take medicines. See the Safety tab for interactions.
Support our free guides: as an Amazon Associate we earn from qualifying purchases. Full disclosure.
